
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
[ad_1] Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including Australia and Taiwan Akebia strengthens cash position modifying Pharmakon loan Auryxia® (ferric citrate) quarterly net product revenue of $40.1 million CAMBRIDGE, Mass., Nov. 8, 2023 /PRNewswire/ — Akebia Therapeutics®, Inc….